{"analyses":[{"ciLowerLimit":"-4.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"8.33","estimateComment":"95% Confidence Interval (CI) for difference in rates were constructed using Anderson-Hauck method.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5612","pValueComment":"P-value was assessed using Cochran-Mantel-Haenszel (CMH) test stratified by the IvRS randomization stratification factors.","paramType":"Difference in Response Rates","paramValue":"1.85","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"81.29","upperLimit":"90.82","value":"86.6"},{"groupId":"OG001","lowerLimit":"83.39","upperLimit":"92.37","value":"88.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"216"}],"units":"Participants"}],"description":"OR was defined as CR, CRi or PR according to IWCLL 2008 criteria. CR required all of the following: peripheral blood lymphocytes below 4x10\\^9/L, absence of lymphadenopathy by physical examination, no hepatomegaly or splenomegaly, absence of disease or constitutional symptoms, blood counts of neutrophils \\>1.5\\*10\\^9/L, platelets \\>100\\*10\\^9/L and hemoglobin \\>110 g/L. PR: two of the following features for at least 2 months: \\>/= 50% decrease in peripheral blood lymphocyte count from the pretreatment value, \\>/=50% reduction in lymphadenopathy, \\>/=50% reduction of liver and/or spleen enlargement, and at least one of the following blood counts: neutrophils \\>1.5\\*10\\^9/L, platelets \\>100\\*10\\^9/L and hemoglobin \\>110 g/L.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.","id":"OG000","title":"Obinutuzumab + Chlorambucil"},{"description":"Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.","id":"OG001","title":"Obinutuzumab + Venetoclax"}],"paramType":"NUMBER","populationDescription":"ITT population was defined as all randomized participants.","reportingStatus":"POSTED","timeFrame":"Day 1 Cycle 7 or 28 days after last IV infusion, approximately 6 months","title":"Percentage of Participants With OR at Completion of Combination Treatment Response Assessment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}